Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. (PTHS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
pths · stock forecast · 3 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Buy
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$66.00
Consensus
$60.50
+130.0% upside
Low
$55.00
Median: $60.5 · Last Close: $26.30
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$60.50
130.0% upside
High Target
$66
151.0%
Low Target
$55
109.1%
Current Price
$26.30
as of today
Based on analyst price targets, the PTHS stock price prediction for the next 12 months ranges from $55 to $66. The consensus PTHS price forecast of $60.50 implies 130.0% upside from the current price of $26.30.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $25.87 | ↓ 1.65% |
1-day model range: $25.75–$25.98. Peak: $25.98 (-1.65%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PTHS · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-15 | Oppenheimer | Maintains | Outperform→Outperform |
| 2026-03-20 | Oppenheimer | Maintains | Outperform→Outperform |
| 2026-03-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-02-26 | Roth Capital | Maintains | Buy→Buy |
| 2026-01-26 | Oppenheimer | Maintains | Outperform→Outperform |
| 2025-11-14 | Oppenheimer | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Pelthos Therapeutics Inc. (PTHS) stock. Of the recent 6 rating actions, 0 were upgrades and 0 were downgrades. 3 analysts currently cover PTHS.
Analyst Recommendation Trends
PTHS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$64M
↓ 62.6% YoY
Revenue Next Year
$118M
↑ 84.6% YoY
EPS This Year
$-10.35
EPS Next Year
$-1.67
↓ 83.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast PTHS EPS of $-10.35 for the current fiscal year, based on estimates from 5 analysts. The PTHS revenue forecast is $64M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PTHS stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PTHS price target is $60.50 (+130.0% upside), with an analyst consensus of Buy.
The PTHS short-term stock prediction for tomorrow is $25.87 (-1.65%).
Pelthos Therapeutics Inc. trades on AMEX under the ticker PTHS. The PTHS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
PTHS forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month PTHS price target is $60.50, with a high forecast of $66.00 and a low of $55.00. The median price target is shown in the chart above when available. This implies +130.0% potential upside from the current price of $26.30.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.